Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intralesional Influenza Vaccine for Patients With Melanoma

NCT04697576 is registered in ClinicalTrials.gov with Carlo Contreras as lead sponsor.

NCT NCT04697576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04697576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intralesional Influenza Vaccine for Patients With Melanoma
Lead sponsor
Carlo Contreras
Phase
Phase 1
Overall status
Recruiting
Start date
October 20, 2021
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage i cutaneous melanoma ajcc v8, clinical stage ia cutaneous melanoma ajcc v8, clinical stage ib cutaneous melanoma ajcc v8, clinical stage ii cutaneous melanoma ajcc v8, clinical stage iia cutaneous melanoma ajcc v8, clinical stage iib cutaneous melanoma ajcc v8, clinical stage iic cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, metastatic melanoma